Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

Company Leans On Domestic Sourcing And Long-Term Contracts To Shield Operations From Trade Disruption.

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.

Tariffs did not prevent Quest from reporting strong margin performance in the first quarter. (Shutterstock)

More from Strategy

More from Medtech Insight